1. |
吕媛, 李耘, 薛峰, 等. 卫生部全国细菌耐药监测网(Mohnarin) 2011-2012 年度血流感染细菌耐药监测报告. 中国临床药理学杂志, 2014, 30(3): 278-288.
|
2. |
李军, 刘清霞, 黄泽炳, 等. 某医院感染病区 2011-2015 年临床分离病原菌及其耐药性. 中国感染控制杂志, 2016, 15(7): 471-475.
|
3. |
何禄娟, 孟婕, 黄大毛, 等. ICU 多重耐药鲍曼不动杆菌血流感染的回顾性分析. 中南大学学报(医学版), 2015, 40(12): 1327-1332.
|
4. |
中华人民共和国卫生部. 医院感染诊断标准(试行). 中华医学杂志, 2001, 81(5): 314-320.
|
5. |
陈佰义, 何礼贤, 胡必杰, 等. 中国鲍曼不动杆菌感染诊治与防控专家共识. 中华医学杂志, 2012, 92(2): 76-85.
|
6. |
Gulen TA, Guner R, Celikbilek N, et al. Clinical importance and cost of bacteremia caused by nosocomial multi drug resistant acinetobacter baumannii. Int J Infect Dis, 2015, 38(9): 32-35.
|
7. |
胡付品, 朱德妹, 汪复, 等. 2015年 CHINET 细菌耐药性监测. 中国感染与化疗杂志, 2016, 16(6): 685-694.
|
8. |
张密, 陈延斌. 鲍曼不动杆菌血流感染 136 例临床分析. 中国感染与化疗杂志, 2016, 16(4): 385-388.
|
9. |
Fu Q, Ye H, Liu S. Risk factors for extensive drug-resistance and mortality in geriatric in patients with bacteremia caused by Acinetobacter baumannii. Am J Infect Control, 2015, 43(8): 857-860.
|
10. |
张银维, 周华, 蔡洪流, 等. 鲍曼不动杆菌血流感染临床特征和死亡危险因素分析. 中华内科杂志, 2016, 55(2): 121-126.
|
11. |
廖纪萍, 孙立颖, 马靖, 等. 泛耐药鲍曼不动杆菌菌血症的临床特点及预后. 中国呼吸与危重监护杂志, 2017, 16(5): 436-440.
|
12. |
Huang ST, Chiang MC, Kuo SC, et al. Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia. J Microbiol Immunol Infect, 2012, 45(5): 356-362.
|
13. |
隆云, 郭清华, 刘大为, 等. 泛耐药鲍曼不动杆菌菌血症危险因素及临床结局. 协和医学杂志, 2015, 6(4): 260-266.
|
14. |
Liu Q, Li W, Du X, et al. Risk and prognostic factors for multidrug-resistant acinetobacter baumannii complex bacteremia: a retrospective study in a tertiary hospital of west China. PLoS One, 2015, 10(6): e0130701.
|
15. |
Tsai MH, Chu SM, Hsu JF, et al. Polymicrobial bloodstream infection in neonates: microbiology, clinical characteristics, and risk factors. PLoS One, 2014, 9(1): e83082.
|
16. |
Gu Z, Han Y, Meng T, et al. Risk factors and clinical outcomes for patients with Acinetobacter baumannii bacteremia. Medicine (Baltimore), 2016, 95(9): e2943.
|
17. |
Chang YY, Liu YM, Liu CP, et al. Impact of reduced tigecycline susceptibility on clinical outcomes of Acinetobacter bacteremia. J Microbiol Immunol Infect, 2017. https://doi.org/10.1016/j.jmii.2017.08.024.
|
18. |
Cheng A, Chuang YC, Sun HY, et al. Excess mortality associated with colistin-tigecycline compared with colistin-carbapenem combination therapy for extensively drug-resistant Acinetobacter baumannii bacteremia: a multicenter prospective observational study. Crit Care Med, 2015, 43(6): 1194-1204.
|
19. |
Liou BH, Lee YT, Kuo SC, et al. Efficacy of tigecycline for secondary Acinetobacter bacteremia and factors associated with treatment failure. Antimicrob Agents Chemother, 2015, 59(6): 3637-3640.
|